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Abstract
Background Acute heart failure (AHF) is a leading cause of death in critically ill patients and is often accompanied by signif-
icant renal dysfunction. Few data exist on the predictive value of measures of renal dysfunction in large cohorts of patients
hospitalized for AHF.
Methods Six hundred and eighteen patients hospitalized for AHF (300 male, aged 73.3 ± 10.3 years, 73% New York Heart
Association Class 4, mean hospital length of stay 12.9 ± 7.7 days, 97% non-ischaemic AHF) were included in a retrospective
single-centre data analysis. Echocardiographic data, serum creatinine/urea levels, estimated glomerular ﬁltration rate (eGFR),
and clinical/laboratory markers were recorded. Mean follow-up time was 2.9 ± 2.1 years. All-cause mortality was recorded, and
univariate/multivariate analyses were performed.
Results Normal renal function deﬁned as eGFR> 90mL/min/1.73m2 was noted in only 3% of AHF patients at baseline. A
signiﬁcant correlation of left ventricular ejection fraction with serum creatinine levels and eGFR (all P< 0.002) was noted.
All-cause mortality rates were 12% (90 days) and 40% (at 2 years), respectively. In a multivariate model, increased age, higher
New York Heart Association class at admission, higher total cholesterol levels, and lower eGFR independently predicted death.
Patients with baseline eGFR< 30mL/min/1.73m2 had an exceptionally high risk of death (odds ratio 2.80, 95% conﬁdence
interval 1.52–5.15, P = 0.001).
Conclusions In a large cohort of patients with mostly non-ischaemic AHF, enhanced serum creatinine levels and reduced
eGFR independently predict death. It appears that patients with eGFR< 30mL/min/1.73m2 have poorest survival rates. Our
data add to mounting data indicating that impaired renal function is an important risk factor for non-survival in patients
hospitalized for AHF.
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Introduction
Acute heart failure (AHF) is a leading cause of death and im-
plies an important burden on healthcare systems worldwide.
AHF is of epidemiologic importance as it accounts for over 1
million hospitalizations and about 300 000 heart-failure-
related deaths annually in the USA alone.1,2 Among the key
ﬁndings in critically ill patients with AHF on today’s intensive
care units is the fact that it may often be accompanied by
comorbidities1,3–5 such as impaired renal function.4,6–14
Although the pathophysiology of AHF-induced acute kidney
injury remains incompletely understood, a number of
pathomechanisms including both haemodynamic and
neurohormonal mechanisms were proposed.1,4,7–12,15,16
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Importantly, chronic kidney disease (CKD) may often be
present as underlying comorbidity in patients with stable
chronic heart failure (CHF).4,7,10,11 Data from large CHF
cohorts demonstrate that up to 60% of CHF patients develop
some degree of CKD.17 Importantly, in patients with stable
CHF, presence of CKD signiﬁcantly affects survival rates, and
previous investigations demonstrate a strong correlation
between glomerular ﬁltration rate (GFR) and risk of
death.4,10,11,14,18 In CHF, data indicate that the risk of death
may even be stronger correlated to a decline in GFR than to
declining left ventricular ejection fraction (LVEF).19
In addition, acute renal failure (ARF) may develop in AHF
that may require renal replacement therapy (RRT).12,20,21
ARF may induce progressive uraemia that worsens the
prognosis of affected patients.22 Importantly, development
of ARF accounts for excess mortality not only in heart failure
patients but also in a general population of critically ill
patients.7,12,18,21,23,24 However, in cases of dialysis-dependent
ARF, optimal timing of RRT25 and optimal mode (i.e. continu-
ous vs. intermittent RRT) remain currently unclear.26–28 This
may especially be the case in haemodynamically instable
patients with AHF.
Little is known about the predictive value of measures of
routine renal function in the subgroup of patients hospitalized
for non-ischaemic AHF. In a large cohort of patients hospital-
ized for non-ischaemic AHF, we therefore aimed to investigate
the prognostic impact of impaired renal function assessed by
serum creatinine/urea levels and estimated GFR (eGFR) on
all-cause mortality.
Methods
Study patients and study design
Between 2001 and 2003, n = 638 Caucasian patients were
hospitalized for AHF. Of those, 618 patients [mean age 73.3
± 10.3 years, 300 male, 449 in New York Heart Association
(NYHA) Class 4] had available data for evaluation of renal
function (i.e. baseline creatinine). Data from admission charts
in a single centre, that is, the General Hospital Murska Sobota
(Slovenia), were analysed in a retrospective fashion. The
retrospective data analysis was approved by the National
Ethics Committee and was performed in accordance with
the Declaration of Helsinki. Patients with clinical and radiolog-
ical evidence of decompensated AHF were included on the
basis of clinical symptoms as established in respective interna-
tional guidelines.29,30 Patients were hospitalized in medical
intensive care/intermediate care units and were treated
according to current international recommendations. Patients
on ambulatory chronic hemodialysis were excluded from the
analysis.
Assessment of renal function, outcome
parameters, and laboratory indices
At admission, serum creatinine levels, serum urea levels,
eGFR, LVEF, high-sensitivity C-reactive protein, white blood
cell count, and other prognostically important laboratory
indices were assessed. Serum creatinine and serum urea
levels were assessed by photometry from heparin plasma
samples. For serum creatinine levels, the Jaffé method of
detection was used (Roche Diagnostics, Mannheim, Germany).
For assessment of outcome, the 28days mortality, length of
hospital stay, total follow-up time, NYHA status at discharge,
and other clinical indices were recorded. eGFR was assessed
using the modiﬁed diet in renal disease formula31: GFR
(mL/min/1.73m2) = 186 × (Scr/88.4)
1.154 × (age)0.203 × (0.742
if female). Although the degree of CKD remains unclear in the
present cohort (please also refer to limitations section of dis-
cussion), study patients were grouped according to disease se-
verity Stages 1–5 equivalent to severity stages proposed for
CKD. The following stages applied: Stage 1 (increased risk;
GFR> 90mL/min/1.73m2), Stage 2 (mild severity; GFR
60–89mL/min/1.73m2), Stage 3 (moderate severity; GFR
30–59mL/min/1.73m2), Stage 4 (severe disease; GFR
15–29mL/min/1.73m2), and Stage 5 (very severe disease;
GFR< 15mL/min/1.73m2).
Statistical analysis
Statistical analyses were performed using MedCalc 9.0.1.1
software (MedCalc Software, Mariakerke, Belgium) and
StatView 5 (SAS Institute, Cary, North Carolina, USA). All data
are expressed as means ± SD and were tested for normal
distribution using the Kolmogorov–Smirnov test, if not indi-
cated otherwise. The relationship of baseline variables with
survival was assessed by Cox proportional-hazard analysis
(univariate and multivariate analyses). Odds ratios (ORs) and
95% conﬁdence interval (CI) for risk factors are given.
Kaplan–Meier cumulative survival curves are displayed for
illustrative purposes. Comparison between curves was
performed by Mantel–Haensel log-rank test. Signiﬁcance
was assigned when P< 0.05.
Results
Study population
A total of 618 Caucasian patients [mean age 73.3 ± 10.3 years,
300 male (48.5%), mean length of in-hospital stay 12.9
± 7.7 days, 100% NYHA Classes 3 and 4, CHADS score 2.4 ± 1.0]
hospitalized on a medical intensive care unit for AHF were
included in this analysis. Data on patients’ demographics in re-
spective equivalent stages of renal dysfunction and laboratory
data are presented in Table 1. Of the overall sample, n = 152
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(25%) patients presented with clinical signs of severe ﬂuid
overload (pleural effusion, pulmonary oedema, and peripheral
oedema). Eighteen patients of the overall sample (3%) were
considered to have AHF because of reasons related to
acute ischaemia, that is, acute myocardial infarction
(AMI). n = 160 patients (26%) of the overall samples initially
presented in a hypertensive (initial systolic blood
pressure ≥ 140mmHg) state (mean systolic blood pressure
in hypertensive subjects 151.4 ± 13.4mmHg). At initial pre-
sentation, atrial ﬁbrillation was present in n = 320 patients
(52%), and n = 281 (i.e. 88%) of these patients were found
to have chronic atrial ﬁbrillation. At hospital admission, 22%
of all patients had previous evidence for ischaemic heart
disease or history of AMI (11%). Major concomitant diseases
at hospital admission were as follows: arterial hypertension
(44%), diabetes mellitus (33%), anaemia 29% (according to
World Health Organization deﬁnitions), chronic obstructive
pulmonary disease (17%), hyper-lipoproteinaemia (12%),
thyroid disease (7%), and gout (5%). In the study population,
patients with advanced age and male gender were more
likely to be found in higher renal disease severity categories
(Table 1). Co-medication at admission consisted in the
following drugs at baseline: angiotensin-converting-enzyme
inhibitors 78% plus angiotensin II receptor antagonists 8%
(mean enalapril equivalent dose 11.0 ± 10.1mg), 48% anti-
arrhythmic drugs/beta-blockers, statins (20%), diuretics
(83%), spironolactone (44%), and digoxin (37%). Mean
amount of total medications 6.2 ± 1.9 per patient (with
4.4 ± 1.6 cardiovascular medications).
Assessment of cardiac function and cardiac injury
Assessment of cardiac function by means of echocardiogra-
phy was performed in 63% of all cases at admission. A signi-
ﬁcant decline of LVEF was found with advanced stages of
renal dysfunction (Stages 1 vs. 4, P = 0.01, Table 1). A direct
correlation of LVEF with serum creatinine (r =0.2,
P = 0.001) and eGFR (r = 0.2, P = 0.002) but not with urea
levels (r =0.07, P = 0.27) was identiﬁed. Mean left ventricu-
lar end-diastolic diameter (LVEDD) was 25.9 ± 26.8mm
(median 6.6, 25th–75th percentile: 5.2–55.0), and mean left
ventricular end-systolic diameter (LVESD) was 20.6 ± 22.1mm
(median 5.4, 25th–75th percentile: 3.9–44.0) at admission.
LVEDD and LVESD were both found to correlate signiﬁcantly
with LVEF (both P< 0.0003) but not with serum creatinine,
serum urea, or eGFR (all P> 0.4). Overall, mean systolic and di-
astolic blood pressures were 129.3±18.8 and 77.7±10.0mmHg,
respectively. The mean heart rate was 113.3 ± 29.9 beats per
minute at admission. For laboratory assessment of cardiac
injury, serum creatinine phosphokinase (CPK) levels were
assessed in 80.1% of all admissions (Table 1). CPK was not
found to correlate with LVEF, eGFR, serum creatinine, or
serum urea levels (all P> 0.25).Ta
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An explorative subgroup analysis was performed in AHF
patients grouped for diastolic (deﬁned as LVEF> 40%) vs.
systolic AHF. A signiﬁcant difference in eGFR was noted
between these two subgroups. In detail, eGFR was 53.4
± 18.9 (diastolic AHF) vs. 47.6 ± 16.0 (systolic AHF)
mL/min/1.73m2 (P = 0.0069). Correspondingly, serum crea-
tinine levels were higher in patients with systolic AHF
[i.e. 117.7 ± 46.9 vs. 104.3 ± 33.5 (diastolic AHF) mL/min/
1.73m2, P = 0.01]. Nevertheless, mean age in patients with
systolic AHF was higher (72.6 ± 9.8 vs. 69.7 ± 11.4 years,
P = 0.02), and NYHA class at admission was higher also
(3.8 ± 0.4 vs. 3.7 ± 0.5, P = 0.004). No between group differ-
ences were noted in regard to serum levels of uric acid,
total cholesterol, alanine aminotransferase, and C-reactive
protein (all n.s.).
Assessment of renal function, renal injury, and
associated comorbidities
Of 618 hospitalized patients for AHF, n = 20 patients (i.e. 3.2%)
had an eGFR of above 90mL/min/1.73m2, which was consid-
ered the lower limit of normal (Table 1). The major proportion
(59.5%) of patients presented with Stage 3 equivalent renal
dysfunction (eGFR 30–59mL/min/1.73m2). This demonstrates
severe renal impairment in most study patients (Table 1). A
highly signiﬁcant correlation of eGFR with serum creatinine
(r=0.677), serum urea (r=0.581), and serum potassium
(r=0.2284) was found (all P< 0.0001). Throughout CKD,
equivalence stages of renal dysfunction, white blood cell
counts, platelet counts, total cholesterol, CPK, aspartate ami-
notransferase, and alanine aminotransferase (data not shown)
were rather unchanged (Table 1).
Impact of measures of renal and cardiac function
on outcome prognostication
Details on univariate and multivariate analyses are given in
Table 2. In the respective single predictor model for sur-
vival, pronounced effects on survival were observed for
the following variables: age, NYHA class at admission, eGFR,
serum levels of urea, serum levels of uric acid, and total
cholesterol (Table 2). Interestingly, higher cholesterol levels
were associated with improved survival rates, a fact previ-
ously known as the cholesterol paradox.32 Moreover, LVEF,
serum creatinine levels, potassium, white blood cell count,
haemoglobin, and diastolic blood pressure were noted to
signiﬁcantly impact on survival. In the multivariate model
for survival, the following variables were included: age,
NYHA class at admission, eGFR, haemoglobin, and total
cholesterol (please refer to Table 2). For illustrative pur-
poses, Kaplan–Meier survival estimate curves were con-
structed for 2 years (Figure 1A) and 1 year follow-up
(Figure 1B and C). All-cause mortality 30 days after hospital
admission was 6% and was 12% (Day 90), 18% (Day 180),
27% (after 1 year), 40% (after 2 years), and 49% (after
3 years), respectively. The mean survival time of patients
surviving the initial episode of AHF was 1115.5 ± 753.7 days
(median 1115.5 days, 25th–75th percentile 322.0–1689.0).
For further assessment of impact of renal function on out-
come measures, ORs were calculated after grouping of
patients to the following eGFR categories: <30mL/min/
1.73m2 and <60mL/min/1.73m2. In patients with an initial
eGFR< 30mL/min/1.73m2, the OR for death was deter-
mined as OR 2.80, 95% CI 1.52–5.15, P = 0.001. In the sub-
group of patients with baseline eGFR< 60mL/min/1.73m2,
the odds for death were 1.94 (95% CI 1.36–2.76,
P = 0.0003).
Table 2 Univariate and multivariate survival models in patients hospitalized for acute heart failure
Single predictor model for non-survival Multivariable model for non-survival
Variable Hazard ratio (95% CI) P-value χ2 Hazard ratio (95% CI) P-value χ2
Age (1 year increase) 1.034 (1.022–1.045) <0.0001 38.2 1.028 (1.015–1.041) <0.0001 19.0
Gender (male) 1.09 (0.891–1.332) 0.40 0.7 — — —
Aetiology of heart failure (non-ischaemic) 1.204 (0.936–1.548) 0.15 2.1 — — —
LVEF (>40%/≤40%)*, increase by 1% 0.986 (0.973–0.999) 0.03 4.6 * * *
NYHA class at admission (per 1 class up) 1.981 (1.547–2.536) <0.0001 33.0 1.68 (1.261–2.239) 0.0004 12.6
Creatinine (10 μmol/L increase) 1.014 (1.004–1.024) 0.006 6.0 — — —
eGFR (per 1mL/min/1.73m2 increase) 0.987 (0.981–0.992) <0.0001 21.2 0.988 (0.982–0.995) 0.0006 11.9
Urea (10mg/dL increase) 1.062 (1.043–1.082) <0.0001 34.3 — — —
Uric acid (10 μmol increase) 1.017 (1.009–1.025) <0.0001 17.1 — — —
Potassium (1mmol/L increase) 1.379 (1.131–1.682) 0.0016 9.9 — — —
White blood cell count (1/nL increase) 1.027 (1.009–1.046) 0.0033 6.2 — — —
Haemoglobin (1 g/dL increase) 0.992 (0.987–0.997) 0.0012 10.0 0.996 (0.991–1.002) 0.20 1.6
Diastolic BP (10mmHg increase) 0.979 (0.967–0.991) 0.0004 12.4 — — —
Total cholesterol (10mg/dL increase) 0.835 (0.763–0.912) <0.0001 17.6 0.885 (0.808–0.97) 0.009 6.8
BP, blood pressure; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; NYHA, New
York Heart Association.
—Not included to multivariable model.
*Not included to multivariable model due to missing data.
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Discussion
In the current analysis, we investigate the impact of renal
dysfunction as assessed by a baseline single-serum creatinine
measurement on the outcomes of critically ill patients hospi-
talized for decompensated AHF. In a large cohort of AHF
patients, we observed that mortality is signiﬁcantly increased
with advancing stages of renal dysfunction when patients
were grouped according to GFR stages equivalent to the
stages suggested for patients with CKD. Our ﬁndings add to
few previous reports demonstrating a relationship between
outcomes and renal dysfunction in patients hospitalized for
AHF. As the vast majority of our study population suffered
from non-ischaemic AHF, our results suggest that these
effects apply also in this subpopulation of AHF.
Interestingly, 97% of AHF patients presented with impaired
renal function as deﬁned by eGFR of >90mL/min/1.73m2 at
baseline. In detail, the study cohort investigated here consists
of AHF patients with mostly moderate kidney disease at
admission (60%, Table 1). When compared to previously
published data, the overall severity of renal impairment seems
in line with most published CHF cohorts, and distribution of
age and gender as well as all-cause mortality rates may be
considered comparable.4,7,10,21 Thus, we believe our study
cohort reﬂects a rather typical cohort of patients hospitalized
for AHF. Nevertheless, as mentioned before, our cohort may
be distinguished from previous investigations as in our
investigation, mostly patients with non-ischaemic AHF were
included.
Epidemiological data including data from larger cohorts of
patients with CHF demonstrate that CKD may be present in
up to 50% of affected patients.7,17,22,33–35 In addition, it
seems pivotal to note that estimation of acute-on-chronic
renal dysfunction in this speciﬁc cohort may be regarded
especially difﬁcult. Nevertheless, although we aimed to
investigate the effect of initial eGFR on long-term outcomes,
we cannot fully elucidate the degree of CKD in the cohort
under investigation. On the other hand, we believe that is
important to investigate the impact of renal dysfunction on
the cohort under investigation. In our univariate and multi-
variate outcome models, we identiﬁed eGFR as one of the
most important risk factors for death in this cohort of acute
care patients. Additional independent predictors of death in
our multivariate outcome model were increased age and
NYHA class at admission as well as decreased haemoglobin
levels, and total cholesterol levels. The latter association
was previously referred to as ‘cholesterol paradox’.32
The authors are well aware of respective limitations that
are primarily driven by study design. First, as discussed
before, we cannot comment on the degree of underlying
CKD in our cohort because of reasons of missing pre-clinical
serum creatinine data. In addition, assessment of course of
both serum creatinine levels and urinary output was beyond
Figure 1 The 2 years (A) and 1 year (B) and (C) Kaplan–Meier survival
estimates in patients hospitalized for acute heart failure according to
estimated glomerular ﬁltration rate categories are given (overall sample
n = 618). (A) The 2 years survival estimates for acute heart failure patients
with mild (full line), moderate (dashed line), and severe (dotted line) re-
nal dysfunction. (B) The 1 year survival estimates for patients with normal
to mildly reduced (full line), moderately reduced (dashed line), and
severely to very severely (dotted line) reduced renal function. (C) The
1 year survival estimates for patients with normal to moderately (full
line), severely (dashed line), and very severely (dotted line) reduced renal
function.
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the scope of our analysis. We are therefore unable to investi-
gate our cohort in regard to the recently established
AKIN/RIFLE criteria and thus focus on initial eGFR as read
out. Second, our analysis is of retrospective single-center
nature, and respective limitations apply. Nevertheless, we
focused on long-term follow-up. With a mean follow-up
period of 2.9 ± 2.1 years, we believe that a rather long obser-
vational period may be regarded a strength of our analysis.
Third, in the clinical setting of acute decompensated heart
failure, serum creatinine levels and eGFR may only partially
reﬂect renal dysfunction. This seems the fact as respective
indices should not be considered in a steady state. However,
this well-known effect is a major challenge in regard to all
respective investigations both of retrospective and prospec-
tive nature. Fourth, we used eGFR rather than measured
GFR for assessment of renal dysfunction. Nevertheless, due
to the speciﬁc kinetics of the underlying condition, GFR
estimating equations may be considered even more accurate
than 24 h urine creatinine clearance studies. Nevertheless,
eGFR equations theoretically assume stable kidney function,
and respective data must therefore be interpreted with
caution. In addition, a potential best eGFR equation is still
under debate. Importantly, we would like to highlight the fact
that here, GFR categories are used in equivalence to well-
known severity stages as proposed for CKD and should not
be misinterpreted as CKD stages. Fifth, we focused on all-
cause mortality as read-out because cardiovascular events,
re-hospitalization, or renal-related outcome measures were
not recorded. Sixth, a minority of patients had some previous
evidence for ischaemic heart disease or history of AMI. Thus, a
minor effect of ischaemia-induced AHF may inﬂuence our
data. Seventh, due to the speciﬁcs of the underlying condition
(i.e. CHF), serum creatinine levels and thus eGFR may be
inﬂuenced by additional factors such as malnutrition or
muscle wasting,36 limb amputation, liver cirrhosis, or others.
Although we are convinced that our study population consists
in a typical cohort of AHF patients, we cannot exclude an
effect of some degree on respective data.
Conclusions
In the present retrospective investigation in a large cohort of
patients with mostly non-ischaemic AHF, we observed that
eGFR independently predicts survival. It appears that patients
with eGFR< 30mL/min/1.73m2 have poorest survival rates.
Our results add to mounting data indicating that the degree
of renal dysfunction is of pivotal importance in a population
of patients with (mostly non-ischaemic) AHF.
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